Sprycel (dasatinib) - CML - Chronic Myeloid Leukemia
''Dasatinib, also known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibband sold under the trade name Sprycel®. Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinases inhibitorapproved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also being assessed for use in metastaticmelanoma.
The drug is named after one of the inventor chemists, Jagabandhu Das, who was a member of the large discovery and development team at Bristol Myers Squibb.''
Extract of Wikipedia
VIDEOS
What are the efficacy and safety considerations of dasatinib therapy?
April 29, 2016, MediCom Oncology
Sprycel®(dasatinib) in the Second-Line Setting
February 17, 2015, OncLiveTV
Sprycel®, a new medication for CML – Dr Lipton
March 28, 2007, For Your Life
What are the efficacy and safety considerations of dasatinib therapy?
April 29, 2016, MediCom Oncology
Sprycel®(dasatinib) in the Second-Line Setting
February 17, 2015, OncLiveTV
Sprycel®, a new medication for CML – Dr Lipton
March 28, 2007, For Your Life
ARTICLES
Long-term results of frontline dasatinib in chronic myeloid leukemia
February 6, 2020, MDlinx
Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group
January 1, 2020, PubMed
Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
November 26, 2019, Nature.com
The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up
November 13, 2019, ASH2019
Update on Dasatinib Use in Chronic‐phase Chronic Myeloid Leukemia
September 25, 2019, docwire
Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
August 26, 2019, Dovepress
Dasatinib shows promise as a control agent for CAR T cells
July 5, 2019, MDedge
Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
September 2018, PubMed
The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia
August 12, 2018, PubMed
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
August 9, 2018, PubMed
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
August 2018, Springer Link
EC approves expanded indication for Sprycel
July 6, 2018, thepharmaletter
Dasatinib Approved in Europe for Pediatric Ph+ Chronic Phase CML
July 5, 2018, OncLive
Maintenance therapy with dasatinib administrated every other day in patients with chronic myeloid leukemia
May 17, 2018, EHA 2018
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
May 3, 2018, PubMed
Dasatinib: A Safe and Effective Option for Pediatric CML
March 5, 2018, Cancer Therapy Advisor
Dasatinib dose management for the treatment of chronic myeloid leukemia
January 25, 2018, Cancer
Pepsi® or Coke®? Influence of acid on dasatinib absorption
January 1, 2018, PublMed
Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)
December 2017, ASH 2017
Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
December 2017, ASH 2017
Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP)
December 2017, ASH 2017
Interim Results of the Canadian Tyrosine Kinase Inhibitor
Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)
December 2017, ASH 2017
Dasatinib increases endothelial permeability leading to pleural effusion
October 14, 2017, European Respiratory Journal
Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
August 25, 2016, European Respiratory Journal
New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment
June 3, 2016, NCBI
Newer Generation TKIs May Be More Effective Than Imatinib for CP-CML
March 30, 2016 , Cancer Therapy Advisor
Dasatinib Commonly Induces Lymphocytosis in CML Patients
March 29, 2016, CancerNetwork
What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature
February 2016, PublMed
Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients
December 7, 2015, ASH 2015
Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias
December 7, 2015, ASH 2015
Velocity of Early BCR-ABL Transcript Elimination As an Optimized Predictor of Deep Molecular Response in Chronic Myeloid Leukemia Patients in Chronic Phase on Treatment with Dasatinib
December 7, 2015, ASH 2015
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib
December 7, 2015, ASH 2015
Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
December 5, 2015, ASH 2015
Bristol-Myers Leukemia Drug Sprycel®'s US Label Updated
August 14, 2015, Yahoo News
FDA Approves Labeling Update to Include New Sprycel® Data
August 13, 2015, Cancer Therapy Advisor
An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML)
June 2, 2014, 2014 ASCO Annual Meeting
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study
February 14, 2014, Blood Journal
Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase
December 2013, DocGuide.com
Dasatinib Shows Promise for Pediatric CML, ALL Patients
September 13, 2013, Cancer Network
Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F
September 5, 2013, Experimental Hematology & Oncology
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
April 2013, Research Gate
Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
October 29, 2012, PublMed
A trial of dasatinib and BMS-833923 for chronic myeloid leukaemia (CA180323)
October 22, 2012, Cancer Research UK
Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus
October 1, 2012, PublMed
Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
September 15, 2012, PublMed
Dasatinib Achieves Higher Response Rate Than Imatinib in CML
September 6, 2012, Cancer Network
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first line dasatinib
May 29, 2012, Journal Blood
Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives
January 15, 2012, PubLMed
Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells
December 19, 2011, Nature
FDA Drug Safety Communication: Sprycel® (dasatinib) and risk of pulmonary arterial hypertension
November 10, 2011, U.S. Food and Drug Administration
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia
July 1, 2011, European Respiratory Journal
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes
June 2011, 2011 ASCO Annual Meeting
Dasatinib Shows Superior Efficacy and Acceptable Tolerability, Supporting First-Line Use in Newly Diagnosed CML-CP
June 3 , 2011, Monthly Prescribing Reference
FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
October 28, 2010, FierceBiotech
Dasatinib, an immodulator?
August 2010, Journal Blood
Pleural effusions due to dasatinib
July 16, 2010, PublMed
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia - Dasatinib is associated with increased risk of bleeding
July 9, 2009, Journal Blood
Targeted therapies for CML: practical considerations and comparisons
August 10, 2008, HemOncToday
Dasatinib suppresses in vitro natural killer cell cytotoxicity
April 15, 2008, Journal Blood
Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
April 8, 2008, PublMed
Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia
October 15, 2007, American Journal of Respiratory and Critical Care Medicine
Dasatinib effective in treating resistant CML cases
January 21, 2006, The Pharmaceutical Journal
Long-term results of frontline dasatinib in chronic myeloid leukemia
February 6, 2020, MDlinx
Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group
January 1, 2020, PubMed
Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
November 26, 2019, Nature.com
The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up
November 13, 2019, ASH2019
Update on Dasatinib Use in Chronic‐phase Chronic Myeloid Leukemia
September 25, 2019, docwire
Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
August 26, 2019, Dovepress
Dasatinib shows promise as a control agent for CAR T cells
July 5, 2019, MDedge
Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
September 2018, PubMed
The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia
August 12, 2018, PubMed
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
August 9, 2018, PubMed
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
August 2018, Springer Link
EC approves expanded indication for Sprycel
July 6, 2018, thepharmaletter
Dasatinib Approved in Europe for Pediatric Ph+ Chronic Phase CML
July 5, 2018, OncLive
Maintenance therapy with dasatinib administrated every other day in patients with chronic myeloid leukemia
May 17, 2018, EHA 2018
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
May 3, 2018, PubMed
Dasatinib: A Safe and Effective Option for Pediatric CML
March 5, 2018, Cancer Therapy Advisor
Dasatinib dose management for the treatment of chronic myeloid leukemia
January 25, 2018, Cancer
Pepsi® or Coke®? Influence of acid on dasatinib absorption
January 1, 2018, PublMed
Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)
December 2017, ASH 2017
Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
December 2017, ASH 2017
Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP)
December 2017, ASH 2017
Interim Results of the Canadian Tyrosine Kinase Inhibitor
Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)
December 2017, ASH 2017
Dasatinib increases endothelial permeability leading to pleural effusion
October 14, 2017, European Respiratory Journal
Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
August 25, 2016, European Respiratory Journal
New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment
June 3, 2016, NCBI
Newer Generation TKIs May Be More Effective Than Imatinib for CP-CML
March 30, 2016 , Cancer Therapy Advisor
Dasatinib Commonly Induces Lymphocytosis in CML Patients
March 29, 2016, CancerNetwork
What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature
February 2016, PublMed
Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients
December 7, 2015, ASH 2015
Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias
December 7, 2015, ASH 2015
Velocity of Early BCR-ABL Transcript Elimination As an Optimized Predictor of Deep Molecular Response in Chronic Myeloid Leukemia Patients in Chronic Phase on Treatment with Dasatinib
December 7, 2015, ASH 2015
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib
December 7, 2015, ASH 2015
Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
December 5, 2015, ASH 2015
Bristol-Myers Leukemia Drug Sprycel®'s US Label Updated
August 14, 2015, Yahoo News
FDA Approves Labeling Update to Include New Sprycel® Data
August 13, 2015, Cancer Therapy Advisor
An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML)
June 2, 2014, 2014 ASCO Annual Meeting
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study
February 14, 2014, Blood Journal
Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase
December 2013, DocGuide.com
Dasatinib Shows Promise for Pediatric CML, ALL Patients
September 13, 2013, Cancer Network
Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F
September 5, 2013, Experimental Hematology & Oncology
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
April 2013, Research Gate
Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
October 29, 2012, PublMed
A trial of dasatinib and BMS-833923 for chronic myeloid leukaemia (CA180323)
October 22, 2012, Cancer Research UK
Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus
October 1, 2012, PublMed
Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
September 15, 2012, PublMed
Dasatinib Achieves Higher Response Rate Than Imatinib in CML
September 6, 2012, Cancer Network
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first line dasatinib
May 29, 2012, Journal Blood
Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives
January 15, 2012, PubLMed
Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells
December 19, 2011, Nature
FDA Drug Safety Communication: Sprycel® (dasatinib) and risk of pulmonary arterial hypertension
November 10, 2011, U.S. Food and Drug Administration
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia
July 1, 2011, European Respiratory Journal
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes
June 2011, 2011 ASCO Annual Meeting
Dasatinib Shows Superior Efficacy and Acceptable Tolerability, Supporting First-Line Use in Newly Diagnosed CML-CP
June 3 , 2011, Monthly Prescribing Reference
FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
October 28, 2010, FierceBiotech
Dasatinib, an immodulator?
August 2010, Journal Blood
Pleural effusions due to dasatinib
July 16, 2010, PublMed
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia - Dasatinib is associated with increased risk of bleeding
July 9, 2009, Journal Blood
Targeted therapies for CML: practical considerations and comparisons
August 10, 2008, HemOncToday
Dasatinib suppresses in vitro natural killer cell cytotoxicity
April 15, 2008, Journal Blood
Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
April 8, 2008, PublMed
Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia
October 15, 2007, American Journal of Respiratory and Critical Care Medicine
Dasatinib effective in treating resistant CML cases
January 21, 2006, The Pharmaceutical Journal
